{"name":"R-Pharm International, LLC","slug":"r-pharm-international-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Concomitant treatment","genericName":"Concomitant treatment","slug":"concomitant-treatment","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Concomitant treatment","genericName":"Concomitant treatment","slug":"concomitant-treatment","phase":"phase_3","mechanism":"Concomitant treatment refers to the simultaneous administration of multiple therapeutic agents to enhance efficacy or address multiple disease pathways.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTFBxTGF5Uk1zYU5EMk1RSV9sdUJGNUttbUlZRGozOG1fRngtN3dJY0hHVlhQU1pWMVFlM2k5STlXX2txdm1fR0tmbFpaRjRXVUJjWEk0Y2QwUQ?oc=5","date":"2026-03-10","type":"pipeline","source":"Forbes","summary":"Alexey Repik - Forbes","headline":"Alexey Repik","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQaUZJTHZsQmNtbHc2b2pQRWZvaU9wY1AtUmRvY1hMZXFNTWhHQ3Y2OTRKeG54MjNLaWNsSHRJYnItUnlEb0JIaXRySmttYW9QdWpkVVBTdlVHYngwVkRqaWIzMVYyZW5KV3pad3lPWmZsYVU4ZDk5TUpFRzZOdzVseDNNYw?oc=5","date":"2026-02-20","type":"pipeline","source":"Statista","summary":"Ranking of Russian pharma companies 2020 - Statista","headline":"Ranking of Russian pharma companies 2020","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOZXBHTzhoMkRRTWVTNnpNVnhBRzZCN1NvUXNHT1MwWnNLM2oweEQ3cy00NDFGTXNyT1RQNVNKRkFQSUpnYjhNLVFlenl0M0NMR2tDU0lrNTA1T3VoaS14Qm1KRjZsS1kxYjhRRW5TOThpWEliNDlZc2NSMEFBRmVqVUl2Vkgxbjl0V3FDcFA4NWxuSUVXcnpRLUQzTkp3WjI1LVB2YkNwc25uSkdwcEFvRXh2SW5wTFNFaUdqaU51UEJUMkh0REVQRFZLWmxuc1hfU3o3ZWVpeGVScDNaY2luSg?oc=5","date":"2026-02-19","type":"pipeline","source":"PR Newswire","summary":"Inmar Intelligence awarded renewed Pharmacy Reverse Distribution agreement with Premier, Inc. - PR Newswire","headline":"Inmar Intelligence awarded renewed Pharmacy Reverse Distribution agreement with Premier, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQVUMwaVRicFF0RUNPWHcxaElyUUJlakljWm5nX3lEZDVZMUVkaWlVbEdkXzVqLVBXWTItRlNIcjZFd0ViS0o2cnpRalIzSnJfeC1TaHVmZ0llcmZtUWxYOEhienNFTFdxZ0VqalB5ZW1EdHR1MmthUW9qcXI2SFRyMm85NFVaRXBKV1B0REY1Z3haN2FuVVJRYmUzTjd5QV9feDd6dg?oc=5","date":"2026-01-13","type":"pipeline","source":"pearceip.law","summary":"Pearce IP BioBlast® for the last three weeks ending 9 January 2026 - pearceip.law","headline":"Pearce IP BioBlast® for the last three weeks ending 9 January 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNdHRnUDBWX2VjU2JPUlRmaWNUeW1mdnBoLXQtWGgxOEVCY19DZmtYZk1MMmhyVDN1bVpXQVVRcTViTWpGd1RKWXRPM1cxOU5nUGVpUkpwZWw0Qlp4ZlFOZnMtWXNxSVhSbnUxTC10ZHk1VC1xMjh3NkVUTTF3TVFybTZmaVNsdWRjY2lPYi0xUmRkNXIxZmZoZnhTVUhwS0ZJRC0zejNndDdvcjRySXh5MjZib0VNV19FZ0VyaQ?oc=5","date":"2025-10-16","type":"pipeline","source":"BioPharm International","summary":"Biotech Equipment Market to Approach $144B by 2030: Implications for Pharma R&D - BioPharm International","headline":"Biotech Equipment Market to Approach $144B by 2030: Implications for Pharma R&D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNT1pOV0lrMzBTaGl1NGJ6M0I2WGluTzhJeHM2dnhZSmthMHZ6ai1EaWRwQ2pkY1F4Y0hEWDJSOGw1NWRReDlDeHV4Q211UU4xUk93LWsweEs0Y3JyT2wwNkM2eVJFdm5NMk1pclgyT1ZGTVhOSkkyX3B6RTJPTmx3WUpHRHZUWkFWOC1taFpmUnVhcFMzWUprQmFSak9XeUl3QnNGaThoX1lkbng5b3RuN0s0MVZhdG8?oc=5","date":"2025-08-05","type":"pipeline","source":"reuters.com","summary":"Moscow-based pharma firm sues Raiffeisenbank for 337.5 million euros - reuters.com","headline":"Moscow-based pharma firm sues Raiffeisenbank for 337.5 million euros","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNdWVvbWc4VmJUUlExWHh5aFhBb0NxOEJudHV4LWRqQTRhOVBfOGdneTZFNFVkcFhlYnEwRUluMHFvMFFOWDV1SXgxN0gzV1hJR05CLTQ0YXlYYkxjelVITVBuRXFRUXd5dDRTV0pNX3dKUmcyZFU2dTFvUEZCUzZKRWxPRWRWbEh4b3d6ZDN2THJZX1JtWThlWk4ySkwzUFJQWFFQMG5Ram1LenpuSmRadWlvYnJVS2tqVXpGenptaWJnQTdzTk84VkxFRUd3bnNDeHlENkMzOXQ?oc=5","date":"2025-06-26","type":"regulatory","source":"Newswire Canada","summary":"XTANDI® (enzalutamide) now funded in Ontario for all approved prostate cancer indications - Newswire Canada","headline":"XTANDI® (enzalutamide) now funded in Ontario for all approved prostate cancer indications","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOMkktSERuaUZPSm82X1JQRkZjeDNxNHNfUjNoRDVweEpqQzFIc1JqOWUtT1k1SEVvVDdZcGc3X0h6bS05X2VfYlQzX2trd09LeU1sUnJjWG1TeFRkRXcteC12NjhjZ0RBWVJVX1dtVFRReExmOXZZUE1tMWFaN0FDSFlpcHlJelB4Zi1FVmZ4MHFMRDR4b3hCaU9FMVVNUmN5c09kczVsa3c1VHFvcVFJS0c4eXVjaG1xamFsNTVB?oc=5","date":"2025-05-26","type":"pipeline","source":"Baku.ws","summary":"The Azerbaijani pharmaceutical plant \"R-PHARM\" has signed an agreement with the Russian company Gerof - Baku.ws","headline":"The Azerbaijani pharmaceutical plant \"R-PHARM\" has signed an agreement with the Russian company Gerof","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPQWpwcFk2VjBYSlpzcWRVbWVPN1RrWFBHdTlnTEVxRHJiRF9ON1YwRzh1UG5iOUVTRTlFMmluN25uNGxZWWcwckJIZ2FwS1dyakNYNkZKYWFnc3ZXNzhHN1I4NzdiWFJLZkFUVHU1QUVSZVRmNmRQbkFkUXZ5cTFDOGxiVDFsMVpjVmhULQ?oc=5","date":"2025-04-23","type":"pipeline","source":"TradeImeX","summary":"Russia Pharmaceutical Imports | List of Pharmaceutical Import Companies in Russia - TradeImeX","headline":"Russia Pharmaceutical Imports | List of Pharmaceutical Import Companies in Russia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxORjRWSDFyVFNqenJnYVgybGZSaUNQM3NDaEw1Zmk2TmIwcXJ3VDZBd1pQUnRQclIya3Q4enR3aEM2UG5RUzZMMmlkN1JzMjNoYkNPTUcxMi0ySTFtU2FuakxhdVBkbk1lb1VHS0hQbTg4M1FoWVJvSzNLN2JzMHRJZVk2WlN2cWxHUmlBZ0Q4LWhJV0NscTFNMkhEeW5oYVpxeGJEczdR?oc=5","date":"2024-08-12","type":"trial","source":"American Heart Association Journals","summary":"Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment–Elevation Myocardial Infarction","headline":"Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With R","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE5RckxOb1lQbWJoU0JxRFRHT0JsOUwtNDBySFYzeUZMNEpWM1EyaWxRMW1zLTJxZlczSU5FRzBGajVGbTUzTlFjZExoNVlUQVFQMDdtbGtnWXZjLXRkNGZreEFpelh3dkE0OEE?oc=5","date":"2022-10-04","type":"patent","source":"Wiley Online Library","summary":"Oncology biosimilars: New developments and future directions - Bachu - 2022 - Cancer Reports - Wiley Online Library","headline":"Oncology biosimilars: New developments and future directions - Bachu - 2022 - Cancer Reports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE03QTBIZUQxMmItR0lERkRpcWZXZzVac09ubDJMek5MaldXNTktOGlPUEdHS01XRWNnRFhzZExaS0g0SUlsaWtNeVZKenJ2OF9TV3lYYUpaLTN1eHhQZVpVOTcyNjlVdlp6eHVjUw?oc=5","date":"2017-04-27","type":"pipeline","source":"mitsui.com","summary":"Mitsui to Participate in the Russian Pharmaceutical Company R-Pharm | 2017 | Releases - mitsui.com","headline":"Mitsui to Participate in the Russian Pharmaceutical Company R-Pharm | 2017 | Releases","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}